FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

| OMB A | PPR | O\ | /AI |
|-------|-----|----|-----|
|-------|-----|----|-----|

| Ì | OMB Number: | 3235-0287 |
|---|--------------------------|-----------|
| | Estimated average burden | |
| | hours per response: | 0.5 |

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934

| | | | of decitor 30(ii) of the investment dompany Act of 1340 | | | | | |
|--|---------------|----------|---|---|--|--|-----------------------|--|
| Name and Address of Reporting Person* Desmarais John M | | | 2. Issuer Name and Ticker or Trading Symbol BioRestorative Therapies, Inc. [BRTX] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner | | | | |
| (Last) 230 PARK AVENU | (First) JE | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 09/26/2016 | | Officer (give title below) | | Other (specify below) | |
| (Street) NEW YORK | NY | 10169 | 4. If Amendment, Date of Original Filed (Month/Day/Year) 09/28/2016 | 6. Indivi | ividual or Joint/Group Filing (Check Applicable L Form filed by One Reporting Person Form filed by More than One Reporting Per | | | |
| (City) | (State) | (Zip) | | | | | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 3. Transac Code (Ir 8) | | 4. Securities Ad Disposed Of (D | | | Securities Beneficially Owned | or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---------------------------------|--|---------------------------------|---|------------------------------------|---------------|-------|----------------------------------|-------------------------------|---|
| | | Code | v | Amount | (A) or (D) | Price | (Instr. 3 and 4) | | (msu. 4) |
| Common Stock | 09/26/2016 | P | | 80,000 | A | \$3 | 455,000 | D | |

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transac Code (li 8) | | Derivative | | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | Beneficial Ownership (Instr. 4) |
|---|---|--|---|---------------------------------|---|------------|---------|--|--------------------|--|----------------------------------|---|--|--|---------------------------------------|
| | | | | Code | v | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | Transaction(s) (Instr. 4) | | |
| Option | \$4.4 | | | | | | | (1) | 12/01/2025 | Common Stock | 15,000 | | 15,000 | D | |
| Warrant | \$5 | | | | | | | 12/17/2015 | 11/17/2020 | Common Stock | 125,000 | | 125,000 | D | |
| Warrant | \$5 | | | | | | | 03/18/2016 | 03/18/2021 | Common Stock | 250,000 | | 250,000 | D | |
| Warrant | \$4.5 | 09/26/2016 | | D ⁽²⁾ | | | 444,444 | (2) | 11/18/2016 | Common Stock | 444,444 | (2) | 0 | D | |
| Warrant | \$4.5 | 09/26/2016 | | A ⁽²⁾ | | 444,444 | | (2) | 11/18/2017 | Common Stock | 444,444 | (2) | 444,444 | D | |
| Warrant | \$5 | 09/26/2016 | | D ⁽³⁾ | | | 400,000 | (3) | 03/18/2017 | Common Stock | 400,000 | (3) | 0 | D | |
| Warrant | \$5 | 09/26/2016 | | A ⁽³⁾ | | 400,000 | | (3) | 03/18/2018 | Common Stock | 400,000 | (3) | 400,000 | D | |
| Option | \$3.73 | | | | | | | (4) | 06/10/2026 | Common Stock | 35,000 | | 35,000 | D | |
| Warrant | \$4 | | | | | | | 06/30/2016 | 06/30/2021 | Common Stock | 40,000 | | 40,000 | I ⁽⁵⁾ | Trust |
| Warrant | \$4 | 09/26/2016 | | P | | 80,000 | | 09/26/2016 | 09/26/2021 | Common Stock | 80,000 | \$0 | 80,000 | D | |

Explanation of Responses:

- 1. The option vests to the extent of 5,000 shares on each of December 1, 2016, 2017 and 2018.
- 2. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of November 18, 2016. The warrant expiration date was extended one year to November 18, 2017.
- 3. The two reported transactions involved an amendment of an outstanding warrant, resulting in the deemed cancellation of the "old" warrant and the grant of a "replacement" warrant. The warrant was originally granted on March 18, 2016 with an expiration date of March 18, 2017. The warrant expiration date was extended one year to March 18, 2018.
- 4. The option vests to the extent of 11,667 shares on each of June 10, 2016 and June 10, 2017, and 11,666 shares on June 10, 2018.
- 5. The warrant is held by a trust established by the Reporting Person for the benefit of his immediate family. The Reporting Person serves as a trustee of the trust.

/s/ Fred Skolnik, by power of attorney, for John M. Desmarais

12/19/2016

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.